Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[\(^{18}F\)]-Fluoro-L-Thymidine ([\(^{18}F\)]FLT) Positron Emission Tomography (PET)
View/ Open
Author
Ullrich, Roland T.
Zander, Thomas
Neumaier, Bernd
Koker, Mirjam
Waerzeggers, Yannic
Borgman, Christa L.
Tawadros, Samir
Li, Hongfeng
Sos, Martin L.
Backes, Heiko
Wolf, Jürgen
Jacobs, Andreas H.
Thomas, Roman K.
Winkeler, Alexandra
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1371/journal.pone.0003908Metadata
Show full item recordCitation
Ullrich, Roland T., Thomas Zander, Bernd Neumaier, Mirjam Koker, Takeshi Shimamura, Yannic Waerzeggers, Christa L. Borgman, et al. 2008. Early detection of erlotinib treatment response in NSCLC by 3′-Deoxy-3′-[\(^{18}F\)]-Fluoro-L-Thymidine ([\(^{18}F\)]FLT) positron emission tomography (PET). PLoS ONE 3(12): e3908.Abstract
Background: Inhibition of the epidermal growth factor receptor (EGFR) has shown clinical success in patients with advanced non-small cell lung cancer (NSCLC). Somatic mutations of EGFR were found in lung adenocarcinoma that lead to exquisite dependency on EGFR signaling; thus patients with EGFR-mutant tumors are at high chance of response to EGFR inhibitors. However, imaging approaches affording early identification of tumor response in EGFR-dependent carcinomas have so far been lacking. Methodology/Principal Findings: We performed a systematic comparison of 3′-Deoxy-3′-[\(^{18}F\)]-fluoro-L-thymidine ([\(^{18}F\)]FLT) and 2-[\(^{18}F\)]-fluoro-2-deoxy-D-glucose ([\(^{18}F\)]FDG) positron emission tomography (PET) for their potential to identify response to EGFR inhibitors in a model of EGFR-dependent lung cancer early after treatment initiation. While erlotinib-sensitive tumors exhibited a striking and reproducible decrease in [\(^{18}F\)]FLT uptake after only two days of treatment, [\(^{18}F\)]FDG PET based imaging revealed no consistent reduction in tumor glucose uptake. In sensitive tumors, a decrease in [\(^{18}F\)]FLT PET but not [\(^{18}F\)]FDG PET uptake correlated with cell cycle arrest and induction of apoptosis. The reduction in [\(^{18}F\)]FLT PET signal at day 2 translated into dramatic tumor shrinkage four days later. Furthermore, the specificity of our results is confirmed by the complete lack of [\(^{18}F\)]FLT PET response of tumors expressing the T790M erlotinib resistance mutation of EGFR. Conclusions: [\(^{18}F\)]FLT PET enables robust identification of erlotinib response in EGFR-dependent tumors at a very early stage. [\(^{18}F\)]FLT PET imaging may represent an appropriate method for early prediction of response to EGFR TKI treatment in patients with NSCLC.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592703/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10198625
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)